Optimizing Apheresis Starting Material Collections for Stem Cell Gene Therapy Manufacturing for Patients with Genetic Hemoglobinopathies (26EL-662)

This program will provide an overview of gene therapy for hemoglobinopathies like sickle cell disease and beta-thalassemia illustrating gene editing strategies. The faculty will also explore the challenges inherent in the complex logistics of preparing, mobilizing, and collecting these patients and discuss potential solutions for optimizing these processes.

Presented by

• Director/Moderator: Ronit Slotky, PhD, MSc, CABP, Director, Cell Therapies Manufacturing Facility, Hackensack University Medical Center, Hackensack, NJ
  Speakers:

  • Patricia Brunker, MD, DPhil, Medical Director, Blood Transfusion Service, Patient Services and Apheresis Clinic, Massachusetts General Hospital, Boston, MA
  • John P. Manis, MD, Boston Children Hospital, Boston, MA

Learning objectives

After participating in this educational activity, participants should be able to:

• Overview of the current available gene therapy treatments for sickle cell disease and beta-thalassemia.
• Discuss challenges in mobilization and collection of patients with genetic diseases.
• Describe strategies for optimization of mobilization and collection of HPC, apheresis in patients with hemoglobinopathies

Registration

Registration includes access to both the live and on-demand version of this eCast. Registration for the live eCast will close 1 hour prior to the eCast start time. If you register after this time, you will receive access to the on-demand eCast when it is available.

For additional information and to register as a single viewer or group, visit the AABB event webpage. Please note: Registration fees are required for AABB events